MARKET

MTCR

MTCR

Metacrine, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.01
-0.09
-0.89%
Opening 12:41 09/21 EDT
OPEN
10.23
PREV CLOSE
10.10
HIGH
10.28
LOW
9.79
VOLUME
76.84K
TURNOVER
--
52 WEEK HIGH
16.19
52 WEEK LOW
9.79
MARKET CAP
259.47M
P/E (TTM)
-7.7929
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
U.S. IPO Weekly Recap: Snowflake's IPO Breaks Records In A Diverse 15-IPO Week
In the busiest week yet for the 2020 IPO market, 15 IPOs raised $8.7 billion.Snowflake took the spotlight, completing the largest software IPO ever and bagging the biggest billion-dollar pop in two decades.Eight SPACs joined the week's diverse group of IPOs.
Seekingalpha · 2d ago
Metacrine Priced 6.54M Share IPO @$13/Share
Metacrine, Inc. (NASDAQ: MTCR) announced the pricing of its initial public offering of 6,540,000 shares of its common stock at a public offering price of $13.00 per share.
Benzinga · 5d ago
Metacrine prices IPO at $13
Metacrine (MTCR) has priced its IPO of 6.54M at $13.00/share, for expected gross proceeds of ~$85M.Underwriters' over-allotment is an additional 981K shares. Trading kicks off September 16. Closing date is
Seekingalpha · 5d ago
IPO Outlook For The Week: Snowflake and Amwell Lead Busy 12 IPO Lineup
Benzinga took a look at high profile IPOs coming in the second half of 2020. Six of those 13 companies could price the week of September 14. Here is a look at the 12 companies expected to go public.
Benzinga · 09/13 14:29
Metacrine sets IPO terms
NASH biotech, Metacrine (MTCR) to raise $85M by offering 6.5M shares at a price range of $12 - $14.Metacrine is a clinical-stage biopharmaceutical company focused on discovering and developing differentiated
Seekingalpha · 09/09 18:52
Metacrine Seeks U.S. IPO For NASH Pipeline Advance
Metacrine has filed to raise $100 million in an IPO. The firm is developing treatments for NASH and other GI diseases. MTCR seeks the funding to advance its pipeline into Phase 2 trials.
Seekingalpha · 09/02 07:30
U.S. IPO Weekly Recap: The IPO Market Gears Up For Fall With Wave Of Filings In A 2 IPO Week
Two foreign electric vehicle makers and three SPACs went public this past week.A wave of filings brought 27 companies into the IPO pipeline.Three SPACs raised $1.6 billion this week.
Seekingalpha · 08/30 18:43
Metacrine' lead drug Fast Track'd for NASH
The FDA designates Metacrine's (MTCR) lead program, MET409 for Fast Track review for the treatment of non-alcoholic steatohepatitis ((NASH)).MET409 targets farnesoid X receptor ((FXR)) a protein which plays a key role in modulating said diseases.Recently,
Seekingalpha · 08/25 20:59
More
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.60%
Pharmaceuticals & Medical Research
-3.26%
Key Executives
Chairman/Co-Founder/Director
Richard Heyman
President/Chief Executive Officer/Director
Preston Klassen
Chief Financial Officer/Primary Contact
Trisha Millican
Senior Vice President
Nicholas Smith
Vice President - Operations
Eric Bischoff
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About MTCR
Metacrine, Inc. is a United States-based biotechnology company. The Company is engaged in developing therapeutics for metabolic diseases. The Company leverages approximately two mechanistically distinct programs to target type 2 diabetes, NASH and other metabolic diseases and liver disorders. The Company focuses on advancing research in nuclear hormone receptors for treatment of metabolic diseases.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Metacrine Inc stock information, including NASDAQ:MTCR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MTCR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MTCR stock methods without spending real money on the virtual paper trading platform.